Document Detail

Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?
MedLine Citation:
PMID:  23046412     Owner:  NLM     Status:  Publisher    
It has been more than 2000 years since Hippocrates described renal disease and observed its progressive nature. Decreased survival and deteriorated health status of these patients' being is attributed to cardiovascular disease. There is increasing interest regarding the impact of non-traditional risk factors, including hyperphosphatemia, elevated calcium-phosphate (CaxPO(4)) product, elevated parathyroid hormone levels and extensive use of calcium-containing phosphate binders on vascular calcification. There is a mounting body of evidence implying that a holistic and methodic approach should clearly suggest starting the battle against vascular calcification early in the course of chronic kidney disease. Type of phosphate binder used should be carefully selected, especially in the presence of vascular calcification.
Pavlos Malindretos
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-9
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  -     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Achillopoulion General Hospital, Department of Nephrology , Polymeri 134, Volos, Magnesia 38222 , Greece
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Crystal structures of Cg1458 reveal a catalytic lid domain and a common catalytic mechanism for FAH ...
Next Document:  PAGED: a pathway and gene-set enrichment database to enable molecular phenotype discoveries.